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OBJECTIVES: To assess the proportion of patients initiated on
statin treatment among patients of various cardiovascular risk
groups and the probability of statin treatment given certain LDL-
levels in daily practice. METHODS: From the PHARMO-
database, we selected patients who had an LDL-measurement in
2006 and no statin use in the year before. Per category of LDL-
levels, i.e. 2.5, 2.6–4.0, 4.1–5.0 and >5.0 mmol/l, we deter-
mined the proportion of patients treated within 6 months after
the measurement among those with cardiovascular disease
(CVD, group I), with diabetes type 2 and no CVD (DM2, group
II), and without CVD or DM2 (group III). The association
between LDL-levels and statin treatment was determined using
logistic regression adjusting for age, gender, CVD and DM2.
RESULTS: Group I included 14,267 patients, group II 9,224
patients, and group III 54,102 patients. Overall, the proportions
of patients receiving statins within 6 months after LDL-
measurement were 19% for group I and II and 8% for group III.
These proportions ranged from 8%, 6% and 2% for patients
with baseline LDL-levels 2.5 mmol/l, to 49%, 43% and 32%
in patients with LDL-levels >5.0 mmol/l. Multivariate modelling
showed that compared to patients with LDL 2.5 mmol/l
(reference) the relative probability of statin treatment increased
with LDL-levels: RR 2.6 (2.4–2.9) for 2.6–4.0 mmol/l, RR 5.8
(5.3–6.3) for 4.1–5.0 mmol/l, and RR 11.9 (10.9–13.1) for
>5.0 mmol/l. Patients with CVD (RR 2.0 (1.9–2.1)) or DM2 (RR
2.5 (2.4–2.7)) were more likely to receive statin treatment. CON-
CLUSIONS: This study shows that, as expected, among statin-
naïve patients the probability of statin treatment following LDL
measurement increased with higher LDL-levels and pre-existing
morbidity. However, the potential to further improve health out-
comes exists because, even among patients with known CVD
or DM2, approximately 55% of patients with LDL levels
>5.0 mmol/l did not receive statin treatment.
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OBJECTIVES: It has been hypothesized that patients suffering
from cardiovascular diseases (CVD) and diabetes type 2 (DM2)
beneﬁt most from treatment with statins. In this study, we deter-
mined the proportion and characteristics of patients who, despite
recommendations in treatment guidelines, were not treated with
statins METHODS: Patients registered with a GP in the IPCI-
PHARMO GP database at January 1, 2007 that had a history of
CVD without DM2 (Group I) or DM2 without CVD (Group II)
were selected. The proportion of patients using statins between
July 2006 and June 2007 was determined among individual
cohorts of patients suffering either from CVD (Group I) or DM2
(Group II). Factors associated with non-treatment with statins
were identiﬁed and quantiﬁed using logistic regression modelling.
RESULTS: In our database we could identify and classify 19,623
CVD patients (Group I) and 5,007 DM2 patients (Group II). Of
these patients, statins were not used by 71% of Group I members
nor by 54% of Group II members. Multivariate modelling
showed that low-socioeconomic status and younger age were
signiﬁcantly (p < 0.05) associated with under-treatment with
statins, both among high risk patients suffering from either CVD
or DM2. CONCLUSIONS: From this study we can conclude
that a very large percentage of patients with established cardio-
vascular risk factors or diabetes where not treated with statins as
recommended in treatment guidelines. Detailed analyses showed
that younger patients and patients with a low-socio economic
status were more likely to not be receiving statins.
PCV3
COMPARISON OF GOAL ATTAINMENT RATES BETWEEN
USERS OF SIMVASTATIN 40 MG AND OTHER STATINS
Heintjes E1, Plat A1, Sturkenboom MC2, Penning-van Beest FJA1,
Herings RMC1
1PHARMO Institute, Utrecht,The Netherlands, 2Erasmus University
Medical Center, Rotterdam,The Netherlands
OBJECTIVES: The use of simvastatin 40 mg is stated as the
preferred statin treatment in the 2006 Dutch guideline for car-
diovascular risk management. We studied whether this recom-
mendation showed equal or better goal attainment rates in
routine daily practice compared to patients treated with other
statins. METHODS: Using the PHARMO data network we iden-
tiﬁed all patients starting statin use in the period 1999 through
2006. Patients suffering from cardiovascular disease or diabetes
type 2 were classiﬁed as high risk. Treatment goals were deﬁned
according to the guidelines of the European Society of Cardiol-
ogy (2003). Goals for total cholesterol (TC) and low density
lipoprotein cholesterol (LDL-C) were <4.5 and <2.5 mmol/l for
high risk patients and <5.0 and <3.0 mmol/l for low risk patients.
Patients at goal at baseline were excluded. Goal attainment rates
at 12 months were compared between simvastatin 40 mg and
other statins and doses using logistic regression adjusting for age,
gender, year of statin use, CVD, DM2, baseline LDL-C and
adherence. RESULTS: We identiﬁed 7356 new statin users of
which 70% were categorised as being at high risk. Goal attain-
ment rates were similar in the low and in high risk patient
groups. Fifty-eight percent of patients treated with simvastatin
40 mg attained goal. Both atorvastatin 20 and 40 mg (RR 1.16
and 1.22) and rosuvastatin 10 and 20 mg (RR1.18 and 1.51)
yielded signiﬁcantly higher goal attainment rates compared to
patients treated with simvastatin 40 mg. CONCLUSIONS:
Results from this study strongly suggest that even after correction
of differences in dosing and baseline LDL-C levels, goal attain-
ment with statins in the ﬁrst year of treatment is signiﬁcantly
more frequent among patients using atorvastatin or rosuvastatin
than in patients using simvastatin 40 mg. Other studies suggest
that these differences translate into reduced cardiovascular risk.
This evidence from routine daily practice questions whether
recommending simvastatin 40 mg is most beneﬁcial to patients.
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OBJECTIVES: To evaluate the effectiveness of sirolimus-eluting
stents (SES) to bare-metal stents (BMS) in a subgroup of patients
with and without diabetes. METHODS: In the prospective
GERSHWIN study in 35 hospitals in Germany, patients with
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coronary artery disease (CAD) undergoing percutaneous coro-
nary intervention (PCI) were electively treated with SES or BMS
(sequential control design). Baseline socio-demographic and
coronary risk factors, major adverse coronary events (MACE),
including death, myocardial infarction, coronary artery bypass
surgery and re-PCI in target vessel, as well as disease-related
direct and indirect costs were documented by standardised ques-
tionnaires completed by patients and physicians through 18
months following PCI. All results are adjusted for age, gender,
household status, 3-vessel heart disease and number of stents.
P-values are from tests of interaction. RESULTS: From April
2003 to June 2005, 658 patients were treated with SES (87%
male, mean age 63  9, 24% diabetic) and 294 patients with
BMS (79% male, mean age 64  10, 20% diabetic). After 18
months, 23% of SES and 27% of BMS patients with diabetes had
suffered MACE in comparison to 9% of SES and 18% of BMS
patients without diabetes (no signiﬁcant difference in the effect of
SES in the presence of diabetes, adjusted = 0.354). In diabetic
patients, SES and BMS incurred total costs of EUR 14,357
and 10,909, respectively. In non-diabetic patients, SES and
BMS costs totalled EUR 13,241 and 11,215, respectively (p
adjusted = 0.164). In diabetic patients, the cost-effectiveness of
SES vs. BMS was EUR 92,400 per patient free from MACE and
in non-diabetic patients, EUR 16,163. CONCLUSIONS: In this
subgroup analysis, MACE in patients with diabetes did not
appear to be inﬂuenced by stent type, whereas in non-diabetic
patients SES use resulted in lower MACE. SES implantation was
less cost-effective in patients with diabetes than in non-diabetic
patients.
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OBJECTIVES: Use of niacin extended-release with statin mono-
therapy (SM) for combined lipid target attainment (CLTA) of
LDL-C, HDL-C, and triglycerides (TG) has been limited. The
objective was to compare real-world CLTA among patients
receiving niacin extended-release+any statin (NER+S) versus
ﬁxed-dose simvastatin+ezetimibe (S+E) combination therapy.
METHODS: A retrospective analysis was conducted on patients
aged 18 years, newly initiating NER+S or S+E therapy between
July 1, 2000–June 30, 2006 (index date), with health plan eligi-
bility of at least 12 months pre- and post-index date, and at
non-target HDL-C (<40 mg/dL) and TG levels (>150 mg/dL) at
index date using a large integrated research claims database.
CLTA, assessed at the last laboratory visit within 12 months of
index date, was deﬁned according to NCEP ATP III, ADA, and
AHA Women’s guidelines where appropriate. A propensity score,
controlling for differences in index date age, gender, LDL-C,
HDL-C, and TG levels, was included as a covariate in a multi-
variate logistic regression model comparing odds of achieving
CLTA between treatment groups. RESULTS: A total of 883
patients were analyzed, 445 initiating NER+S and 438 initiating
S+E. NER+S patients were signiﬁcantly older (54  9 years
vs. 51  8 years; p < 0.0001), more male (81% vs. 55%;
p < 0.0001), hypertensive (80% vs. 67%; p < 0.0001), and with
prior cardiovascular disease (CVD) (46% vs. 17%; p < 0.0001)
than S+E patients. All NER+S patients and some S+E patients
(48%) were prescribed SM prior to index date. Mean baseline
values for LDL-C (98  36 vs. 136  43 mg/dL; p < 0.0001)
and HDL-C (37  9 vs.44  11 mg/dL; p < 0.0001) were signiﬁ-
cantly lower among NER+S patients. Logistic regression analysis
indicated 64% (OR: 1.64; 95% C.I.: 1.02–2.61) increased like-
lihood of CLTA among NER+S patients versus S+E patients.
CONCLUSIONS: Dyslipidemia patients initiating NER+S
therapy were more likely to achieve CLTA than patients initiating
S+E therapy in a real-world setting, thus implying a greater
potential reduction in cardiovascular risk.
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OBJECTIVES: To assess the effectiveness of clopidogrel in addi-
tion to aspirin versus aspirin alone after acute coronary syn-
drome (ACS) in an Australian context. METHODS: A Markov
model was constructed to simulate the onset of major cardiovas-
cular events (composite of myocardial infarction, ischemic stroke
and cardiovascular death), major bleeding events and non-
cardiovascular death in a representative cohort of 1000 subjects
experiencing ACS. In the ﬁrst year post ACS, underlying risks
of events were drawn from the nationwide Australian Acute
Coronary Syndromes Prospective Audit (ACACIA) registry
(n = 2553). In subsequent years, risks from Australian partici-
pants of the Reduction in Atherothrombosis for Continued
Health (REACH) registry (n = 2567) were used. Decision analy-
sis compared the two interventions and follow-up was simulated
for ten years. Relative risks of cardiovascular and bleeding events
associated with clopidogrel were drawn from the Clopidogrel in
Unstable Angina to Prevent Recurrent Events (CURE) trial, and
assumed to be sustained as long as subjects remained on treat-
ment. Uncertainty analyses were undertaken via Monte Carlo
simulation. RESULTS: The modeled outcomes from the simu-
lated follow-up of 1000 subjects in the ten year model were
major CV events, major bleeding events and deaths. There were
fewer CV events and deaths in the clopidogrel arm but more
bleeding events than aspirin. The number needed to treat (NNT)
to avoid a major CV event was 14 (9–29); to avoid a death was
33 (14–207). Overall, there were 8413 life years gained in clo-
pidogrel compared with 8191 in aspirin alone. CONCLUSIONS:
In the simulated cohort, the addition of clopidogrel to aspirin
represents a highly effective strategy for the secondary prevention
of death and cardiovascular events following ACS. Although
there is a small increase in bleeding in the simulated cohort, the
net effect remains a signiﬁcant prevention of cardiovascular
events, saving of lives and years of life gained.
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OBJECTIVES: The aim of this systematic review (SR) is to
compare efﬁcacy and safety of bosentan, epoprostenol, iloprost,
sildenaﬁl and treprostinil with conventional treatment (CT)
in patients with pulmonary arterial hypertension (PAH).
METHODS: Analysis was performed according to “Polish
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